Supernus Pharma (NASDAQ: SUPN) reported Q1 EPS of $0.43, $0.19 better than the analyst estimate of $0.24. Revenue for the quarter came in at $152 million versus the consensus estimate of $150.47 million.

GUIDANCE:

Supernus Pharma sees FY2023 revenue of $640-680 million, versus the consensus of $683 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.